349 related articles for article (PubMed ID: 31963784)
1. The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History.
P De Koning H
Trop Med Infect Dis; 2020 Jan; 5(1):. PubMed ID: 31963784
[TBL] [Abstract][Full Text] [Related]
2. Priorities for the elimination of sleeping sickness.
Welburn SC; Maudlin I
Adv Parasitol; 2012; 79():299-337. PubMed ID: 22726645
[TBL] [Abstract][Full Text] [Related]
3. History of sleeping sickness (African trypanosomiasis).
Cox FE
Infect Dis Clin North Am; 2004 Jun; 18(2):231-45. PubMed ID: 15145378
[TBL] [Abstract][Full Text] [Related]
4. [Sleeping sickness: one hundred years of control strategy evolution].
Louis FJ; Simarro PP; Lucas P
Bull Soc Pathol Exot; 2002 Dec; 95(5):331-6. PubMed ID: 12696370
[TBL] [Abstract][Full Text] [Related]
5. Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
Abdeen S; Salim N; Mammadova N; Summers CM; Goldsmith-Pestana K; McMahon-Pratt D; Schultz PG; Horwich AL; Chapman E; Johnson SM
Bioorg Med Chem Lett; 2016 Nov; 26(21):5247-5253. PubMed ID: 27720295
[TBL] [Abstract][Full Text] [Related]
6. The origins of a new Trypanosoma brucei rhodesiense sleeping sickness outbreak in eastern Uganda.
Fèvre EM; Coleman PG; Odiit M; Magona JW; Welburn SC; Woolhouse ME
Lancet; 2001 Aug; 358(9282):625-8. PubMed ID: 11530149
[TBL] [Abstract][Full Text] [Related]
7. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa.
Lejon V; Boelaert M; Jannin J; Moore A; Büscher P
Lancet Infect Dis; 2003 Dec; 3(12):804-8. PubMed ID: 14652206
[TBL] [Abstract][Full Text] [Related]
8. Basic Biology of Trypanosoma brucei with Reference to the Development of Chemotherapies.
Dean S
Curr Pharm Des; 2021; 27(14):1650-1670. PubMed ID: 33463458
[TBL] [Abstract][Full Text] [Related]
9. Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies.
Jamabo M; Mahlalela M; Edkins AL; Boshoff A
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569903
[TBL] [Abstract][Full Text] [Related]
10. Trypanosoma brucei: Metabolomics for analysis of cellular metabolism and drug discovery.
Fall F; Mamede L; Schioppa L; Ledoux A; De Tullio P; Michels P; Frédérich M; Quetin-Leclercq J
Metabolomics; 2022 Mar; 18(4):20. PubMed ID: 35305174
[TBL] [Abstract][Full Text] [Related]
11. Current situation of African trypanosomiasis.
Kuzoe FA
Acta Trop; 1993 Sep; 54(3-4):153-62. PubMed ID: 7902654
[TBL] [Abstract][Full Text] [Related]
12. From Colonial Research Spirit to Global Commitment: Bayer and African Sleeping Sickness in the Mirror of History.
Madeja UD; Schroeder U
Trop Med Infect Dis; 2020 Mar; 5(1):. PubMed ID: 32164154
[TBL] [Abstract][Full Text] [Related]
13. Identification of different trypanosome species in the mid-guts of tsetse flies of the Malanga (Kimpese) sleeping sickness focus of the Democratic Republic of Congo.
Simo G; Silatsa B; Flobert N; Lutumba P; Mansinsa P; Madinga J; Manzambi E; De Deken R; Asonganyi T
Parasit Vectors; 2012 Sep; 5():201. PubMed ID: 22992486
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story.
Baker N; de Koning HP; Mäser P; Horn D
Trends Parasitol; 2013 Mar; 29(3):110-8. PubMed ID: 23375541
[TBL] [Abstract][Full Text] [Related]
15. Experiences of the one-health approach by the Uganda Trypanosomiasis Control Council and its secretariat in the control of zoonotic sleeping sickness in Uganda.
Waiswa C; Azuba R; Makeba J; Waiswa IC; Wangoola RM
Parasite Epidemiol Control; 2020 Nov; 11():e00185. PubMed ID: 33015381
[TBL] [Abstract][Full Text] [Related]
16. Sleeping sickness in Uganda: a thin line between two fatal diseases.
Picozzi K; Fèvre EM; Odiit M; Carrington M; Eisler MC; Maudlin I; Welburn SC
BMJ; 2005 Nov; 331(7527):1238-41. PubMed ID: 16308383
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the impact of targeting livestock for the prevention of human and animal trypanosomiasis, at village level, in districts newly affected with T. b. rhodesiense in Uganda.
Hamill L; Picozzi K; Fyfe J; von Wissmann B; Wastling S; Wardrop N; Selby R; Acup CA; Bardosh KL; Muhanguzi D; Kabasa JD; Waiswa C; Welburn SC
Infect Dis Poverty; 2017 Feb; 6(1):16. PubMed ID: 28162093
[TBL] [Abstract][Full Text] [Related]
18. Update on human African trypanosomiasis (sleeping sickness).
Kennedy PGE
J Neurol; 2019 Sep; 266(9):2334-2337. PubMed ID: 31209574
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle.
Matovu E; Seebeck T; Enyaru JC; Kaminsky R
Microbes Infect; 2001 Jul; 3(9):763-70. PubMed ID: 11489425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
